The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.36
Bid: 2.35
Ask: 2.41
Change: 0.23 (10.70%)
Spread: 0.06 (2.553%)
Open: 2.20
High: 2.45
Low: 2.20
Prev. Close: 2.15
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

30 Jun 2023 13:12

RNS Number : 5929E
Immupharma PLC
30 June 2023
 

 

 

RNS: RELEASE 30 June 2023

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

2023 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS PASSED

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below.

 

 

Resolution

For

% For

Against

% Against

Withheld

1. To receive the accounts of the Company for the year ended 31 December 2022 together with the reports thereon of the directors and auditors of the Company

52,114,317

 

99.08

 

482,400

 

0.92

 

49,317

 

2. To re-appoint Dr Sanjeev Pandya as a director of the Company

47,601,452

 

90.55

 

4,964,842

 

9.44

 

79,740

 

3. To re-appoint CLA Evelyn Partners Limited as Auditor of the Company

52,084,178

 

99.08

 

482,400

 

0.92

 

79,456

 

4. That the Directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting

51,003,388

 

98.86

 

585,640

 

1.14

 

1,057,006

 

5. That the Company may send or supply documents or information to members by making them available on a website or other electronic means.

 

 

 

 

52,115,217

 

 

 

99.08

484,400

 

0.92

 

46,417

 

SPECIAL RESOLUTION

6. That, subject to the passing of Resolution 4 the directors be and they are hereby empowered pursuant to section 571 of the Act to allot equity securities (as defined in section 560 of the Act).

51,013,053

99.88

575,975

1.12

1,057,006

 

 

As at the date of the AGM, the number of issued ordinary shares of the Company was 333,403,115 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total.

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

Ends

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chairman and Chief Executive Officer

+44 (0) 207 206 2650

Lisa Baderoon, Head of Investor Relations & Non-Executive Director

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 3550

 

 

+44 (0) 20 3650 3650

 

 

+44 (0) 1483 413500

 

 

 

 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGMZGFVZGMGFZM
Date   Source Headline
14th Sep 202210:04 amRNSWritten Response received from the FDA
7th Sep 20228:25 amRNSExercise of Options
31st Aug 20227:00 amRNSFDA response for Type C Meeting - update
30th Aug 202211:29 amRNSExercise of Options
24th Aug 20228:11 amRNSExercise of Options
17th Aug 20226:12 pmRNSTR-1 Notification of major holdings
16th Aug 20228:03 amRNSTotal Voting Rights
11th Aug 20227:00 amRNSResult of Broker Option / PDMR Dealings
4th Aug 20227:00 amRNSInvestor Presentation - Investor Meet Company
3rd Aug 20224:40 pmRNSSecond Price Monitoring Extn
3rd Aug 20224:35 pmRNSPrice Monitoring Extension
3rd Aug 20224:33 pmRNSSubscription/Placing to raise £1.1m; Broker Option
26th Jul 20224:41 pmRNSSecond Price Monitoring Extn
26th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20227:00 amRNSInitiation of Research
7th Jul 20227:00 amRNSConfirmed FDA response date for Type C Meeting
28th Jun 20225:44 pmRNSAdmission of new ordinary shares of £0.01
28th Jun 202211:42 amRNSResult of AGM
27th Jun 20227:00 amRNSUpdate on Lupuzor
20th Jun 20223:22 pmRNSHolding(s) in Company
1st Jun 20227:00 amRNSNotice of AGM & Annual Report & Accounts
25th May 20227:00 amRNSFinals results for y/e 31 December 2021
4th May 20227:00 amRNSUPDATE on LUPUZOR™ PROGRESS to PHASE 3 with AVION
13th Apr 20227:00 amRNSUPDATE on P140 (LUPUZOR™) clinical progress
7th Feb 20227:00 amRNSLUPUZOR UPDATE
10th Jan 20227:00 amRNSTR-1: Notification of major holdings
5th Jan 20229:53 amRNSTR-1: Notification of major holdings
24th Dec 20218:34 amRNSHolding(s) in Company
20th Dec 20217:00 amRNSSubscriptions and Placing to raise £3.55 million
15th Dec 20214:35 pmRNSPrice Monitoring Extension
7th Dec 20214:41 pmRNSSecond Price Monitoring Extn
7th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20217:00 amRNSCOLLABORATION WITH IMPERIAL COLLEGE LONDON
18th Nov 20217:00 amRNSCorporate Update
8th Nov 20214:41 pmRNSSecond Price Monitoring Extn
8th Nov 20214:36 pmRNSPrice Monitoring Extension
11th Oct 20214:35 pmRNSPrice Monitoring Extension
1st Oct 20217:00 amRNSEuronext Delisting
30th Sep 20217:15 amRNSPROF. SYLVIANE MULLER AWARDED ‘LEGION D’HONNEUR’
29th Sep 20217:30 amRNSInterim Results for the 6months ended 30 June 2021
29th Sep 20217:00 amRNSCorporate Update
22nd Sep 20214:36 pmRNSPrice Monitoring Extension
24th Aug 202111:07 amRNSDirector/PDMR Shareholding
20th Aug 20214:40 pmRNSSecond Price Monitoring Extn
20th Aug 20214:35 pmRNSPrice Monitoring Extension
19th Aug 20214:35 pmRNSPrice Monitoring Extension
17th Aug 20218:50 amRNSNotification of Major Holdings
12th Aug 20217:00 amRNSFDA approves the Lupzuor™ PK study
10th Aug 20214:40 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.